Navigation MenuRealWire Limited

Delivering Relevance, Releasing Influence

Tweet Facebook LinkedIn
Press Release

PAREXEL introduces its Connected Journey™ of newly integrated data-driven services to simplify drug development and commercialisation


Features new ForeSite™ clinical trial methodology designed to reliably predict site success

LONDON, June 19, 2017 – As life science companies increasingly seek to gain insights from diverse data sources to make drug development more efficient and effective, PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, is launching its Connected Journey™ of data-driven services. This newly integrated network, powered by PAREXEL® Analytics capabilities, combines PAREXEL’s technology, processes, and expertise to deliver critical intelligence supporting clinical development and commercialisation.

PAREXEL is focused on expediting activities such as protocol design, study start-up, trial execution, regulatory submission, and product commercialisation. By integrating its data-driven services, PAREXEL has accelerated a number of key processes. These processes include moving more rapidly from final protocol available to last site initiated, accelerating site activation, and achieving faster turnaround times from database lock to clinical study report[1]. As a result, PAREXEL is helping biopharmaceutical clients complete clinical trials 22 percent faster than the industry average[2].

PAREXEL’s Connected Journey consists of more than 40 innovative data-driven services. Its most recent innovation, the ForeSite™ clinical trial methodology, integrates therapeutic area expertise, real-time analytics technology, and centralised oversight to more reliably predict site productivity. The solution enables sponsors to optimise feasibility and site and country selection, as well as to more effectively engage and retain sites and patients.

“While drug companies have access to more data sources than ever before, they face challenges in generating and integrating meaningful insights that drive timely and actionable decisions,” said Mark A. Goldberg, M.D., President and Chief Operating Officer, PAREXEL. “Aggregating and leveraging the right data to drive value requires a broad range of services working together to generate insights across the entire drug development and commercialisation spectrum. We believe PAREXEL’s global scale and broad technical expertise offer clients a uniquely integrated and comprehensive portfolio — delivered by a single provider.”

“The data resources to inform decision making are available, but to yield true value they must all be brought together,” said Xavier Flinois, President, PAREXEL Informatics. “PAREXEL’s Connected Journey moves from single solutions to the industry’s largest system of interrelated data-driven innovations. This model seamlessly connects data, technology, processes and multi-functional expertise, and is designed to foster close collaboration with all constituents.” 

[1] KMR Group - Clinical Group, 2015
[2] KMR Group - Clinical Group, 2015

About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialisation continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the integrated clinical development and regulatory information management process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 86 locations in 51 countries around the world, and had approximately 19,370 employees in the third quarter. For more information about PAREXEL International visit

PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.

This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.

# # #

Sophie Marston/ Ivelina Adzheva
OneChocolate for PAREXEL
Tel.: 0207 437 0227

Ronald Aldridge
Tel.: +1-781-434-4753